Literature DB >> 11814572

Expression of the highly polymorphic Cryptosporidium parvum Cpgp40/15 gene in genotype I and II isolates.

Roberta M O'Connor1, Cheleste M Thorpe, Ana-Maria Cevallos, Honorine D Ward.   

Abstract

The enteric protozoan Cryptosporidium parvum infects intestinal epithelial cells in a wide range of hosts, causing severe gastrointestinal disease. The invasive sporozoite stage most likely attaches to and invades host cells through multiple host receptor/parasite ligand interactions. Preliminary evidence suggests that the glycoprotein products of the Cpgp40/15 gene, gp40 and gp15, are involved in these interactions. In addition, the Cpgp40/15 gene that encodes these glycopeptides is highly polymorphic in genotype I isolates, suggesting that the gene products may be subject to immune selection. In this study, we characterized the Cpgp40/15 gene in a genotype I isolate and compared expression of the Cpgp40/15 gene in isolates of both genotype. Cpgp40/15 is a single copy gene in both TU502 (genotype I) and GCH1 (genotype II) isolates. However, Northern blot analysis revealed the presence of two transcripts, 2.3 and 1.5 kb in size, in mRNA from GCH1 as well as TU502-infected Caco-2A cells. Accumulation of the two Cpgp40/15 mRNAs peaked 12-24 h post-infection. Using 3'RACE analysis, three polyadenylation sites were identified 371, 978 and 1002 bp downstream of the GCH1 Cpgp40/15 stop codon. Two of these polyadenylation sites were also used in TU502. The sequences of the GCH1 Cpgp40/15 3'untranslated regions (3'UTRs) were identical to genomic sequence and shared 96.7% homology with TU502 3'UTRs. Actinomycin D treatment of GCH1-infected Caco-2A cells followed by Northern blot analysis, revealed that the stability of the 1.5 kb message was considerably greater than that of the 2.3 kb transcript.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11814572     DOI: 10.1016/s0166-6851(01)00416-9

Source DB:  PubMed          Journal:  Mol Biochem Parasitol        ISSN: 0166-6851            Impact factor:   1.759


  6 in total

1.  Serum IgG response to Cryptosporidium immunodominant antigen gp15 and polymorphic antigen gp40 in children with cryptosporidiosis in South India.

Authors:  Sitara Swarna Rao Ajjampur; Rajiv Sarkar; Geneve Allison; Kalyan Banda; Anne Kane; Jayaprakash Muliyil; Elena Naumova; Honorine Ward; Gagandeep Kang
Journal:  Clin Vaccine Immunol       Date:  2011-02-02

2.  Antibody responses to the immunodominant Cryptosporidium gp15 antigen and gp15 polymorphisms in a case-control study of cryptosporidiosis in children in Bangladesh.

Authors:  Genève M Allison; Kathleen A Rogers; Anoli Borad; Sabeena Ahmed; Mohammad Mahbubul Karim; Anne V Kane; Patricia L Hibberd; Elena N Naumova; Stephen B Calderwood; Edward T Ryan; Wasif A Khan; Honorine D Ward
Journal:  Am J Trop Med Hyg       Date:  2011-07       Impact factor: 2.345

3.  Cryptosporidiosis in HIV/AIDS patients in Kenya: clinical features, epidemiology, molecular characterization and antibody responses.

Authors:  Jane W Wanyiri; Henry Kanyi; Samuel Maina; David E Wang; Aaron Steen; Paul Ngugi; Timothy Kamau; Tabitha Waithera; Roberta O'Connor; Kimani Gachuhi; Claire N Wamae; Mkaya Mwamburi; Honorine D Ward
Journal:  Am J Trop Med Hyg       Date:  2014-05-27       Impact factor: 2.345

4.  Genetic analysis of a Cryptosporidium parvum human genotype 1 isolate passaged through different host species.

Authors:  D E Akiyoshi; X Feng; M A Buckholt; G Widmer; S Tzipori
Journal:  Infect Immun       Date:  2002-10       Impact factor: 3.441

5.  Expression of Cpgp40/15 in Toxoplasma gondii: a surrogate system for the study of Cryptosporidium glycoprotein antigens.

Authors:  R M O'Connor; K Kim; F Khan; H D Ward
Journal:  Infect Immun       Date:  2003-10       Impact factor: 3.441

6.  Subtyping Cryptosporidium ryanae: A Common Pathogen in Bovine Animals.

Authors:  Xin Yang; Ni Huang; Wen Jiang; Xinrui Wang; Na Li; Yaqiong Guo; Martin Kváč; Yaoyu Feng; Lihua Xiao
Journal:  Microorganisms       Date:  2020-07-24
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.